Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health a...
What impact could this news have on the broader neurodegeneration sector and related biotech stocks?
How might the results influence analyst rating upgrades/downgrades or target price revisions for ATHA?
Will the Phase 1 data trigger any partnership or licensing discussions with larger pharmaceutical firms?
11 days ago